Markets:

Overview

News

Currencies

International

Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

1.843 -0.017 (-0.91%)

Streaming Delayed Price Updated: 1:51 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More ↗

April 17, 2024

Via Benzinga

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More ↗

April 17, 2024

Via Benzinga

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders

April 17, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

April 10, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine CEO Issues Letter to Shareholders

April 09, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More ↗

March 30, 2024

Via Benzinga

Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence ↗

March 29, 2024

Via Benzinga

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression

March 27, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More ↗

March 20, 2024

Via Benzinga

Topics Economy

Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket ↗

March 20, 2024

Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results.

Via Benzinga

Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China

March 19, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review ↗

March 16, 2024

Via Benzinga

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

March 13, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange

March 13, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Podcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors ↗

March 12, 2024

Via Benzinga

Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More ↗

March 04, 2024

Via Benzinga

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

February 27, 2024

From SciSparc Ltd

Via GlobeNewswire

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds

February 27, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds ↗

February 27, 2024

Patent applications by Clearmind Medicine for novel compositions in collaboration with SciSparc. Clearmind's CEO, highlights the significant expansion of IP protection.

Via Benzinga

Topics Intellectual Property

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

February 23, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Next-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 Patents ↗

February 21, 2024

SciSparc & Clearmind file patents for LSD, psilocybin, DMT blends, advancing psychedelic therapeutics for mental health.

Via Benzinga

Topics Intellectual Property

What's Going On With Psychedelic Drug-Developers SciSparc And Clearmind Stock? ↗

February 20, 2024

SciSparc Ltd. and Clearmind Medicine Inc. shares are trading higher Tuesday after the companies announced the submission of three international patent applications as part of the ongoing collaboration...

Via Benzinga

Topics Intellectual Property

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

February 20, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds

February 20, 2024

From SciSparc Ltd

Via GlobeNewswire

Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More ↗

February 15, 2024

Via Benzinga

Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More ↗

February 15, 2024

Via Benzinga

Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China

February 05, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center

February 01, 2024

From Clearmind Medicine Inc.

Via GlobeNewswire

Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More ↗

January 27, 2024

New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...

Via Benzinga

Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

February 01, 2024

Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.